GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Piotroski F-Score

BOLD (Boundless Bio) Piotroski F-Score : N/A (As of Oct. 31, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Boundless Bio has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Boundless Bio's Piotroski F-Score or its related term are showing as below:


Boundless Bio Piotroski F-Score Historical Data

The historical data trend for Boundless Bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Piotroski F-Score Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A N/A

Boundless Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Boundless Bio's Piotroski F-Score

For the Biotechnology subindustry, Boundless Bio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boundless Bio's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Boundless Bio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Boundless Bio's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun24) TTM:Last Year (Jun23) TTM:
Net Income was -13.173 + -12.144 + -15.43 + -16.976 = $-57.72 Mil.
Cash Flow from Operations was -12.189 + -11.686 + -15.776 + -16.236 = $-55.89 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Jun23)
to the end of this year (Jun24) was
(154.931 + 143.738 + 129.894 + 117.077 + 188.203) / 5 = $146.7686 Mil.
Total Assets at the begining of this year (Jun23) was $154.93 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $183.13 Mil.
Total Current Liabilities was $8.96 Mil.
Net Income was -13.125 + -11.779 + -11.719 + -12.398 = $-49.02 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Jun22)
to the end of last year (Jun23) was
(0 + 0 + 76.829 + 0 + 154.931) / 5 = $115.88 Mil.
Total Assets at the begining of last year (Jun22) was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $3.03 Mil.
Total Current Assets was $145.94 Mil.
Total Current Liabilities was $8.15 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Boundless Bio's current Net Income (TTM) was -57.72. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Boundless Bio's current Cash Flow from Operations (TTM) was -55.89. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun23)
=-57.723/154.931
=-0.37257231

ROA (Last Year)=Net Income/Total Assets (Jun22)
=-49.021/0
=

Boundless Bio's return on assets of this year was -0.37257231. Boundless Bio's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Boundless Bio's current Net Income (TTM) was -57.72. Boundless Bio's current Cash Flow from Operations (TTM) was -55.89. ==> -55.89 > -57.72 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun23 to Jun24
=0/146.7686
=0

Gearing (Last Year: Jun23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun22 to Jun23
=3.029/115.88
=0.02613911

Boundless Bio's gearing of this year was 0. Boundless Bio's gearing of last year was 0.02613911. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun24)=Total Current Assets/Total Current Liabilities
=183.132/8.957
=20.44568494

Current Ratio (Last Year: Jun23)=Total Current Assets/Total Current Liabilities
=145.936/8.153
=17.89966883

Boundless Bio's current ratio of this year was 20.44568494. Boundless Bio's current ratio of last year was 17.89966883. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Boundless Bio's number of shares in issue this year was 22.023. Boundless Bio's number of shares in issue last year was 13.99. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Boundless Bio's gross margin of this year was . Boundless Bio's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun23)
=0/154.931
=0

Boundless Bio's asset turnover of this year was 0. Boundless Bio's asset turnover of last year was . ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+1+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Boundless Bio has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Boundless Bio  (NAS:BOLD) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Boundless Bio Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Boundless Bio Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
9880 Campus Point Drive, Suite 120, San Diego, CA, USA, 92121
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.